Collectionner le produit
Détails du produit
Synonyms
4-1BB Ligand, TNFSF9, CD137L
Source
Cynomolgus 4-1BB Ligand, Fc Tag (41L-C5254) is expressed from human 293 cells (HEK293). It contains AA Leu 67 - Glu 251 (Accession # XP_015296398.1) trimer design.
Predicted N-terminus: Pro
Molecular Characterization
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 87.4 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Cynomolgus 4-1BB Ligand, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Cynomolgus 4-1BB Ligand, Fc Tag (Cat. No. 41L-C5254) is more than 90% and the molecular weight of this protein is around 160-196 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human 4-1BB, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. 41B-H5256) at 2 μg/mL (100 μL/well) can bind Cynomolgus 4-1BB Ligand, Fc Tag (Cat. No. 41L-C5254) with a linear range of 0.2-2 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Tumor necrosis factor ligand superfamily member 9
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
2 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
